Tags : April 30

Revance and Mylan to Extend Biosimilar to BOTOX Program Decision

Shots: Revance is in discussion with Mylan regarding whether Mylan plans to move forward or not with the biosimilar to BOTOX program. The expected decision date for Mylan is Apr 30, 2020 or thirty days from the date that Revance provides Mylan with certain deliverables regarding the program In Sept’2019, the companies amended their agreement […]Read More